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Thoracic aortic aneurysm/dissection (TAAD) is a potential lethal condition with a rising incidence. This condition may occur
sporadically; nevertheless, it displays familial clustering in >20% of the cases. Family history confers a six- to twentyfold increased
risk of TAAD and has to be considered in the identification and evaluation of patients needing an adequate clinical follow-
up. Familial TAAD recognizes a number of potential etiologies with a significant genetic heterogeneity, in either syndromic or
nonsyndromic forms of the manifestation. The clinical impact and the management of patients with TAAD differ according to
the syndromic and nonsyndromic forms of the manifestation. The clinical management of TAAD patients varies, depending on
the different forms. Starting from the description of patient history, in this paper, we summarized the state of the art concerning
assessment of clinical/genetic profile and therapeutic management of TAAD patients.
1. Introduction
Thoracic aortic aneurysm/dissection (TAAD) is a potential
lethal condition with a rising incidence and its clinical
impact, as well as the therapeutic management, differs
according to the syndromic or nonsyndromic manifestation.
Thus, the understanding of the family history together with
a comprehensive clinical and genetic evaluation of patients
with TAAD is necessary for clinical diagnosis in order to
achieve a documented differential diagnosis and therapeutic
medical and surgical strategies. Starting from a real-world
clinical case report and referring to the state of the art in the
field, this review aims to summarize the principal diagnostic
phases with the clinical/genetics evaluations allowing the
achievement of the most appropriate management of TAAD
patients.
2. Clinical Relevance of Family History and
Screening Strategies
In September 2006, a 33-year-oldmale (height 193 cm, weight
98 kg, and body surface area 2.29m2) was referred by his
general practitioner to a private cardiologist for the evalua-
tion of systemic arterial hypertension, treated with ramipril
2.5mg o.i.d. and amlodipine 5mg o.i.d. Family history was
positive for fatal type A aortic dissection occurring at 52
years in the patient’s mother. The patient had undergone
surgery for inguinal hernia in 2000 and reported hiatal
hernia andmyopia >3 diopters. At cardiovascular evaluation,
blood pressure was 138/90mmHg; resting ECG showed sinus
rhythm with 74 beats per minute and incomplete right
bundle branch block. Echocardiography evidenced aortic
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33 years, BSA = 2.29m2
predicted aortic size = 0.97 + 1.12 2.29 = 3.53 cm
Measured aortic size = 50mm
Z-score = (5 − 3.53)/0.24 = 6.1; aortic ratio = 1.4
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Figure 1: (a) Parasternal long-axis view of the aortic root and of proximal ascending aorta of our patient, at end-diastole. (b) 95% confidence
limits for aortic root diameter at the sinuses of Valsalva in relation to body surface area in adults younger than 40 years (modified fromRoman
et al. 1989 [1]). In the box, based on the nomogram, predicted size of the aortic root is calculated (3.53 cm) and compared withmeasured aortic
size (5.0 cm) to calculate the 𝑍-score and the aortic ratio.
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Figure 2: Magnetic resonance SSFP-based imaging: (a) a diastolic sinus plane image, showing 3 aortic cusps; (b) SSFP sagittal oblique of the
ascending aorta’s aortic arch and proximal descending aorta. Reportedmeasurements were all performed by orthogonal views at end-diastole.
root ectasia (50mm; 𝑍-score 6.1, aortic ratio (RR) 1.4) and
dilatation of the proximal ascending aorta (42mm) (Figure 1)
associated with a mildly regurgitant tricuspid aortic valve
and with a trivial mitral regurgitation. The left ventricle
was normal in size and function. In order to achieve a full
evaluation of the entire aorta, the patient was submitted to
cardiovascular magnetic resonance (Figure 2) which showed
severe dilatation of the aortic root (47 × 51mm), diffuse
dilatation of the ascending aorta (maximal diameter 42 ×
48mm), and mild dilatation of the aortic arch and of
the proximal descending aorta (31 × 31mm). Therapy was
changed into metoprolol 25mg t.i.d. (with the suggestion to
increase the dosage up to reach target heart rate < 60 bpm)
and amlodipine 5mg o.i.d.
Thoracic aortic aneurysm/dissection (TAAD) is a poten-
tial lethal condition with a rising incidence [2]. Although
this condition may occur sporadically, it displays familial
clustering in >20% of the cases [3–5]. In particular, family
history confers a significant increased (six- to 20-fold) relative
risk of TAAD which is not conveyed by cardiopulmonary
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comorbidity [6]. A positive family history is known to rep-
resent a risk factor for the development of TAAD and can be
considered in the evaluation and identification of patients at
increased risk [7–9]. Evidences exist indicating that between
15% and 30% of patients with an aortic aneurysm and/or
dissection have a positive family history of TAAD risk [7–9].
Thus, an echocardiographic screening of first-degree relatives
of patients with TAAD, as well as in relatives of individuals
affected by conditions in which thoracic aneurysm and
dissection are common clinical features of the disease (e.g.,
Marfan syndrome (MFS), Loeys-Dietz syndrome (LDS), and
bicuspid aortic valve (BAV)), is recommended to favor early
detection and to establish appropriate follow-up and thera-
peutic strategies [10]. Noteworthily, such a screening policy
was not performed in the herein described patient, who
underwent echocardiography for the assessment of potential
organ damage due to arterial hypertension.
Familial TAAD predominantly displays an autosomal
dominant pattern of inheritance, with varying degrees of
penetrance and variable expressivity, although other forms of
inheritance, including recessive patterns, have been reported
[7–9]. In comparison to sporadic TAAD patients, familial
TAAD individuals tend to be younger at presentation, sug-
gesting a more aggressive clinical phenotype [6]. Beyond a
positive family history of TAAD, criteria for diagnosing non-
syndromic familial TAAD include (a) detection of dilatation
at any trait of the thoracic aorta involving either the sinuses of
Valsalva, the ascending aorta, or both and (b) the exclusion of
MFS, LDS, Ehlers-Danlos syndrome vascular type, and other
syndromic causes of TAAD (Table 1).
Transthoracic echocardiography allows adequate assess-
ment of several aortic segments, particularly the aortic root
and proximal ascending aorta. All scanning planes should
be applied to obtain information on most aortic segments
[12]. Particular care should be also used to visualize the
morphology of the aortic valve, since BAV is frequently
associated with dilatation either of the ascending aorta distal
to the sinuses of Valsalva or of the sinuses of Valsalva [13]
and may be a complex familial trait [14]. The diagnosis of
dilatation of the sinuses of Valsalva or of proximal ascending
aorta is based on the comparison ofmeasured aortic diameter
compared with age-appropriate nomograms related to body
surface area (BSA) [1]. Consistently, an aneurysm of the
thoracic aorta (as well as of any other arterial region) is
defined as a permanent localized dilatation having at least
a 50% increase in diameter compared with the expected
normal size [15]. Thus, the ratio between the measured aortic
size and the expected aortic diameter (so-called aortic ratio
(RR)) should be >1.5 to appropriately allow the definition of
aneurysm. Aortic dilatation exceeding the expected one by
<150% is called ectasia/dilatation. Moreover, subtracting the
measured aortic size from the expected aortic diameter and
dividing this number by the standard deviation provided by
the nomogram will supply the aortic 𝑍-score (Figure 1).
When inconclusive information or abnormalities (i.e.,
dilatation ≥ 40mm) are present in the echocardiographic
examination, another imaging modality is required (namely,
computed tomography (CT) scan or magnetic resonance
(MR)) to either complete or add diagnostic assessment [12].
These methods, in fact, allow full visualization on the entire
aorta, independently of the quality of the acoustic windows,
potentially affecting transthoracic echocardiography. How-
ever, for both diagnostic and follow-up purposes, the utiliza-
tion ofCT andMRI appropriate planes and standardized lines
of measurements are mandatory to reduce misclassifications
and subsequently inappropriate therapeutic choices [16].
3. Etiopathogenetic Profile of
Thoracic Aortic Aneurysm/Dissection and
Therapeutic Implications: The Role of
Tertiary Referral Centers
The patient was referred to the Center for the Study of
Aortopathies, Marfan Syndrome, and Related Disorders of
Florence University, for clinical evaluation, genetic counsel-
ing, and, eventually, genetic analysis. At clinical examination,
the patient displayed enophthalmos, malar hypoplasia, ret-
rognathia, pectus carinatum, dorsolumbar scoliosis, reduced
elbow extension, hindfoot deformity, and skin striae. With
the above-described clinical manifestations, the patient was
reclassified as affected by MFS.Thus, we started therapy with
metoprolol 25mg t.i.d. and losartan (starting from 50mg
o.i.d. to reach optimal therapy) and suggested aortic surgery.
The patient was subsequently evaluated by the cardiac sur-
geon of his country’s hospital, who decided to accept him for
surgery pending the result of genetic assessment.
Familial TAAD recognizes a number of potential etiolo-
gieswith a significant genetic heterogeneity (Table 1), in either
syndromic or nonsyndromic forms of the manifestation.
Both forms may include sporadic cases due to “novel/fresh”
mutations. In fact, many genes have been associated with
TAAD and many other potential genes have been localized
on various chromosome regions [4, 5].
TAAD is often part of the clinical manifestations of
pleiotropic inherited connective tissue disorders, with the
principal being MFS. MFS displays an autosomal dominant
inheritance, with a prevalence of 2 per 10,000. Mutations in
FBN1 gene encoding fibrillin 1 have been described in 70–90%
of patients fulfilling MFS diagnosis [11]. Actually, literature
data showed that patients exhibiting suspectedMFphenotype
not harbouring FBN1 mutations were carrier of mutations
in other relevant genes mainly TGFBR1 and TGFBR2 coding
transforming growth factor receptor types 1 and 2 (<3%)
(prevalently associated with LDSs) [11]. Clinical criteria for
MFS diagnosis are represented by TAAD, ectopia lentis, and
systemic features with a score ≥7 (Tables 2 and 3). Presence
of a first-degree relative affected by MFS and the detection
of a pathogenic mutation in FBN1 gene are other two criteria
(Table 2). The presence of at least two criteria (two clinical
or one clinical and one genetic) allows the diagnosis of MFS
according to the revised Ghent criteria [11] (Table 2). The
correct diagnosis of MFS requires a multidisciplinary team
relying on a set of diagnostic criteria which include two dif-
ferent road maps according to the presence of family history
(Table 2), in association with a systemic score describing the
presence of systemic involvement of the disease (Table 3).
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Table 1: Nonsyndromic and main syndromic disorders associated with thoracic aortic aneurysm.
Classification Frequency Gene name Gene symbol Inher.
Nonsyndromic
Aortic aneurysm, familial thoracic 1
(AAT1) Rare — Chr.11q23.3-q24 AD
Aortic aneurysm, familial thoracic 1
(AAT2) Rare — Chr.5q13-q14 AD
Aortic aneurysm, familial thoracic 3
(AAT3) 3% of TAA
Transforming growth factor-beta
receptor, type II TGFBR2 AD
Aortic aneurysm, familial thoracic 4
(AAT4) 1-2% of TAA Myosin, heavy chain 11, smooth muscle MYH11 AD
Aortic aneurysm, familial thoracic 5
(AAT5) 2% of TAA
Transforming growth factor-beta
receptor, type I TGFBR1 AD
Aortic aneurysm, familial thoracic 6
(AAT6) 10–15% of TAA
Actin, alpha-2, smooth muscle, and
aorta ACTA2 AD
Aortic aneurysm, familial thoracic 7
(AAT7) 1% of TAA Myosin light chain kinase MYLK AD
Aortic aneurysm, familial thoracic 7
(AAT8) Rare
Protein kinase, cGMP-dependent,
regulatory, and type I PRKG1 AD
Syndromic
Marfan syndrome 1 : 5,000–10,000 Fibrillin 1 FBN1 AD
Loeys-Dietz syndrome 1 Rare Transforming growth factor-betareceptor, type I TGFBR1 AD
Loeys-Dietz syndrome 2 Rare Transforming growth factor-betareceptor, type II TGFBR2 AD
Loeys-Dietz syndrome 3 or aneurysm
osteoarthritis syndrome Rare
Mothers against decapentaplegic
homolog 3 SMAD3 AD
Loeys-Dietz syndrome 4 Rare Transforming growth factor-beta 2 TGFB2 AD
Loeys-Dietz syndrome 5 Rare Transforming growth factor-beta 3 TGFB3 AD
Vascular Ehlers-Danlos syndrome 1 : 100,000 Collagen, type III, alpha-1 COL3A1 AD
Arterial tortuosity syndrome Rare Solute carrier family 2 (facilitatedglucose transporter), member 10 SLC2A10 AR
In our patient, the clinicalmanifestations are sufficient for
making diagnosis of MFS with the presence of aortic ectasia
(𝑍-score > 2) and systemic features (score = 8: enophthalmos
+ malar hypoplasia + retrognathia (1), pectus carinatum (2),
dorsolumbar scoliosis (1), reduced elbow extension (1), hind-
foot deformity (2), and skin striae (1)) as criteria (Table 3).
The diagnosis of MFS has multiple implications for a
patient, given the more aggressive pattern of the disease in
comparison with other potential etiologies. The implications
regard the need for specificmedical treatment, the counseling
for follow-up, pregnancy and family planning, and advice for
aortic surgery, which are indicated at lower threshold of aortic
size in MFS than in non-MFS patients [17].
A number of studies have assessed the potential role
of multiple therapies in MFS. The pathophysiology of aor-
topathy in MFS constitutes the basis for the use of 𝛽-
blockers, originally proposed to decrease rate of rise of aortic
pressure, although this effect has not been proven in patients
with major aortic dilatation [18–23]. The beneficial effect
of 𝛽-blockade may also be due to the bradycardia-induced
decrease of the rate of stretching of the aortic wall, as well
as to decrease in blood pressure, although the hypotensive
effect of𝛽-blockers has never been evaluated in a randomized
study in normotensive individuals. Similarly, the utilization
of a nondihydropyridinic calcium-channel antagonist in case
of intolerance to 𝛽-blockers is reasonable. Consistently, the
avoidance of stressful, intense physical and sport activities
should be a part of clinical counseling in MFS patients.
Recently, the effectiveness of such a policy in preventing
aortic dissection in a great proportion of MFS patients
has been shown in 732 patients who were followed up for
a mean of 6.6 years [24], further supporting the notion
that 𝛽-blockers are recommended in MFS patients. The
novel interpretation of the pathophysiology of MFS-related
aortopathy based on TGF-𝛽 signaling [25] has resulted in
researches evaluating the potential of TGF-𝛽-antagonism by
ACE-inhibitors and angiotensin II receptor blockers (ARB)
[21, 22, 26]. Groenink et al. (2013) [27] have recently reported
the results of a prospective, randomized, controlled trial indi-
cating a beneficial effect of losartan treatment on aortic root
dilatation rate in adults with MFS. Furthermore, Mueller et
al., in a retrospective cohort of previously untreated pediatric
patients with MFS, demonstrated that both strategies with 𝛽-
blockers or ARB are beneficial in pediatric and adolescent
patients [26].
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Table 2: Revised Ghent criteria for Marfan syndrome diagnosis
(modified from Loeys et al. 2010) [11].
In the absence of family history of MFS
(i) Aortic dilatation∗ (𝑍-score ≥ 2) and Ectopia lentis = MFS
(ii) Aortic dilatation∗ (𝑍-score ≥ 2) and FBN1mutation∗∗ = MFS
(iii) Aortic dilatation∗ (𝑍-score ≥ 2) and systemic score ≥ 7 points
(Table 3) = MFS§
(iv) Ectopia lentis and FBN1mutation with known aortic
dilatation∧ = MFS
In the presence of family history of MFS
(i) Ectopia lentis and familial history of MFS = MFS
(ii) Systemic score ≥ 7 points (Table 3) and familial history of MFS
= MFS§
(iii) Aortic dilatation∗ (𝑍-score ≥ 2 above 20 years old, ≥3 below
20 years) + familial history of MFS = MFS§
∗: aortic diameter at the sinuses of valsalva above indicated𝑍-score or aortic
root dissection.
∗∗FBN1 (fibrillin 1) mutation is defined according to the following criteria:
(i) Mutation previously shown to segregate in Marfan family.
(ii) De novo (with proven paternity and absence of disease in parents)
mutation belonging to one of the five following categories:
(1) nonsense mutation,
(2) in frame and out of frame deletion/insertion,
(3) splice site mutations affecting canonical splice sequence or shown to alter
splicing on mRNA/cDNA level,
(4) missense affecting/creating cysteine residues,
(5) missense affecting conserved residues of the EGF consensus sequence
((D/N)𝑋(D/N)(E/Q)𝑋𝑚(D/N)𝑋𝑛(Y/F) with 𝑚 and 𝑛 representing variable
number of residues; D aspartic acid, N asparagine, E glutamic acid, Q
glutamine, Y tyrosine, and F phenylalanine).
(iii) Other missense mutations: segregation in family if possible and absence
in 400 ethnically matched control chromosomes, if no, family history
absence in 400 ethnically matched control chromosomes.
(iv) Linkage of haplotype for 𝑛 ≥ 6meioses to the FBN1 locus.
∧FBN1 mutation that has been identified in an individual with aortic
aneurysm.
§Caveat: without discriminating features of Sphrintzen-Goldberg syndrome,
Loeys-Dietz syndrome, or vascular form of Ehlers-Danlos syndrome and
after TGFBR1/2, collagen biochemistry, and COL3A1 testing if indicated.
Since then, multiple studies explored this issue with
somehow conflicting results. Lacro et al., among children and
young adults with Marfan’s syndrome who were randomly
assigned to losartan or atenolol, disappointingly found no
significant difference in the rate of aortic root dilatation
between the two treatment groups over a 3-year period
[28]. Moreover, the Marfan Sartan trial showed that the
evolution of the size of the aortic root was not modified
by adding losartan to 𝛽-blocker therapy, discouraging the
utilization of ARB as first-line therapy in these patients [29].
Furthermore, a recent randomized, double-blind trial using
MRI to compare the efficacy of losartan and atenolol, given
as monotherapy, did not demonstrate differences between
treatments in their efficacy to prevent aortic dilation in
MFS [30]. Finally, a recent experimental publication argued
for a treatment strategy that would target both promis-
cuous angiotensin receptors and TGF-𝛽 signaling without
interfering with the early protective role of TGF-𝛽 activity
[31]. Differences among the various study designs, including
doses and combination of various drugs, and differences in
Table 3: Manifestations and signs included in systemic score and
systemic score calculation: maximum score = 20 points; score ≥ 7:
systemic involvement [11].
Manifestations and signs Score
Wrist and thumb sign 3 (wrist or thumb sign: 1)
Pectus carinatum deformity 2 (pectus excavatum orchest asymmetry: 1)
Hindfoot deformity 2 (plain pes planus: 1)
Pneumothorax 2
Dural ectasia 2
Protrusio acetabuli 2
Reduced US/LS and
increased arm/height and
no severe scoliosis
1
Scoliosis or thoracolumbar
kyphosis 1
Reduced elbow extension 1
Facial features (3/5)
1 (dolichocephaly,
enophthalmos,
downslanting palpebral
fissures, malar hypoplasia,
and retrognathia)
Skin striae 1
Myopia > 3 diopters 1
Mitral valve prolapse (all
types) 1
imagingmodality, as well as the characteristics of the enrolled
patients, preclude, anyway, a definite statement regarding
medical treatment inMFS. Overall, the results of the available
studies raise concern on the real effectiveness of any medical
treatment for the overall population ofMFS patients, possibly
due to their wide clinical and genetic heterogeneity. Indeed,
MFS is often seen as a single disease in clinical studies but
in MFS different types of mutations in the same gene as
well as mutations in different genes are involved. Recent data
suggested that Marfan patients with haploinsufficient FBN1
mutations seem to be more responsive to losartan therapy
for inhibition of aortic root dilatation rate compared with
dominant negative patients [32]. We are now interpreting the
results from studies on patients with similar clinical picture
but different genetic mechanisms. While future researches
and planned individual meta-analysis [33] could shed some
light on such discrepancies among studies, the approach on
the single patient basis should be tailored and adjusted based
on a strict clinical, genetic, and instrumental evaluation.
Based on the available data at the moment in which we
assessed the patient, aiming at reducing heart rate at <70 bpm
and at lowering blood pressure, we withhold amlodipine
and choose to associate 100mg of losartan with 25mg of
metoprolol t.i.d.
The diagnosis of MFS also affects indications to prophy-
lactic aortic surgery since death from aortic dissection or
rupture occurs in untreated MFS patients often before 40
years, and dilation of the aortic root is present in 60–80% of
patients [24–27, 34]. In patients with sporadic TAA without
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major connective tissue disease, aortic surgery is recom-
mended when maximal aortic size is ≥55mm, provided that
BAV or ≥5mm/year of increase in aortic size is not shown or
that another cardiac surgery is indicated [17]. In individuals
with MFS, aortic surgery is otherwise recommended when
aortic size is ≥50mm, or ≥45mm when other risk factors
are present.These risk factors include family history of aortic
dissection, rapid increase in aortic size, severe aortic and/or
mitral regurgitation, and desire of pregnancy in women [17].
Patients with TAA, independently of the etiology, should
be reassessed on a periodic basis both clinically and with
appropriate imaging modalities. Behind evaluation of aortic
dilatation, including exploration of symptoms suggestive of
TAA expansion, comprehensive quantitative evaluation of
both aortic andmitral hemodynamic derangement is needed.
Moreover, stringent control of hypertension, smoking cessa-
tion (and avoidance of exposure to environmental tobacco
smoke), lipid profile optimization (based on risk profile),
and other atherosclerosis risk-reduction measures should be
instituted for patients with TAA of any size and etiology,
independently of the indication to surgery. Even if a poor
or complete lack of association of traditional cardiovascular
risk factors with aortic root aneurysm in syndromic and
nonsyndromic disease was observed, the increase in the life
expectancy of the affected patients raises the need to protect
these patients from other atherosclerotic comorbidities and
from the deleterious effect of atherosclerosis on a “fragile”
aortic wall due to alteration of the extracellular matrix and
extracellular matrix remodeling [35]. Finally, patients should
be educated for prompt self-referral to hospital facilities in
presence of chest or back pain.
Therefore, due to (1) the diagnosis of MFS, (2) the aortic
diameter of 50mm at Valsalva sinus, and (3) the positive
family history for aortic dissection, our patientwas referred to
aortic surgery, independently of genetic analysis, which does
not play any role for the indication on timing of surgery in
this patient in whom diagnosis has been fully accomplished
clinically.
Indeed, mutation screening analysis should be applied
to the cases in which clinical features are not sufficient to
reach a final diagnosis [11], for prenatal diagnosis in couples
at risk, or in families in which mortality associated with
aortic aneurysms/dissections along generations is present. In
the latter case, the identification of a pathogenetic mutation
may help in performing prevention and careful follow-up in
younger relatives at risk.
4. Genetic Approaches
Nonetheless, the patient underwent genetic analysis in the
genetic laboratory of theCenter for the Study ofAortopathies,
Marfan Syndrome, and Related Disorders of Florence Uni-
versity for the identification of pathogenetic mutation, after
genetic counseling, due to the need expressed by the patient
for future prenatal diagnosis. Awritten informed consent was
obtained from the patient.
The genetic analysis for the identification of the patho-
genetic mutation in MFS consists of the analysis of the three
major MFS associated genes: FBN1, TGFBR2, and TGFBR1
[11].The analysis workflow starts with the analysis of the FBN1
gene detectable in 70–90% of MFS patients [11, 35–37], and
then, in the case of negative result, it is extended to TGFBR2
and TGFBR1 gene.
Despite the technological advances, the genetic analysis
is still time consuming and relatively expensive and most
importantly requires an expert genetic laboratory. The clas-
sical genetic analysis approach consists of direct sequencing
of the 65 coding exons and intronic flanking regions of FBN1
gene, followed in case of negative result by sequencing of
TGFBR2 (7 exons) and then TGFBR1 (9 exons) coding and
flanking regions by Sanger technology.The direct sequencing
of exons including the intron junction sequences is crucial
to allow the identification of mRNA splicing defects. Once
the putative pathogenetic mutation has been identified, the
genetic laboratory needs to evaluate the “real pathogenicity”
according to criteria reported in Table 2 and/or by using
in silico tools such as SIFT (http://sift.jcvi.org/), Polyphen
(http://genetics.bwh.harvard.edu/pph2/), and Pmut (http://
mmb.pcb.ub.es/PMut/). Figure 3 shows chromatogram
details of an example of FBN1 sequencing analysis and in
silico effect of the identified mutation.
In our patient, the genetic analysis of the three major
MFS genes did not evidence the pathogenetic mutation. This
finding did not override either the previous clinical diagnosis
of MFS or the presence of a mutation in the three major
genes, due to several potential explanations: presence of (1) a
large insertion/deletion involving several exons or the entire
candidate genes (FBN1 or TGFBR2 or TGFBR1) [38–42] and
(2) mosaicism in the three major genes [42–48]. These types
of mutations, already reported in some Marfan syndrome
patients by the literature, are not identified by the Sanger
sequencing approach or require DNA analysis from more
than one kind of cell (fibroblast, lymphocytes, salivary cells,
or gonadal cells) [38–51]. Finally, a further explanation might
be the presence of pathogenetic mutations in genes at present
unknown to be associated with MFS.
On the other hand, syndromes caused bymutations in the
TGF-𝛽-signaling system, causing different forms of Loeys-
Dietz syndrome, can share clinical features with Marfan
syndrome [11]. In these disorders, the genes that might be
mutated include TGFBR1, TGFBR2, TGFB2, TGFB3, and
SMAD3 [52–59]. This patient, at the moment, does not show
any other feature suggestive for TGF-𝛽-pathies such as Loeys-
Dietz syndrome [52–59].
Both in the case of pathogenetic mutation identification
and in the case that no pathogenetic mutation is identi-
fied, the genetic counseling is mandatory to explain the
implication for the investigated subject and for the family
members, especially when the aim of the genetic test is
the possibility of prenatal diagnosis. The genetic counseling
should be performed according to the current legislation of
the specific country.
The development and standardization of high-
throughput sequencing technologies (HTS) or next-
generation sequencing (NGS) also for diagnostic purpose
are determining a lowering of cost and time of analysis [60].
The application of the HTS approach allowing the analysis
of MFS associated genes and genes associated with disorders
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Figure 3: Chromatogram details of the forward and reverse sequencing of FBN1 gene exon 15 and flanking intronic regions. The sequence
(a) shows a pathogenetic missense mutation (c.1906 A>G, p. Arg636Gly) as evaluated by SIFT in silico prediction (b).
in differential diagnosis may determine a better and rapid
definition of the diagnosis and of the genes involved in
the clinical manifestations of the patients with important
implications for the management of the individuals affected
by these complex disorders. Nevertheless, HTS equally
requires the presence in the laboratory of expert biologists/
biotechnologists/bioinformaticians to perform analysis and
mutation pathogenicity evaluation.
5. Conclusions and Take-Home Messages
Our patient successfully underwent valve-sparing aortic
surgery in 2008, by the replacement with a prosthetic tube of
the aortic root and of the ascending aorta. Four months after
the intervention, the patient experienced a paroxysmal atrial
fibrillation which was effectively cardioverted electrically.
Since then, the patient is controlled on a yearly basis.
In 2011, transthoracic echocardiography detected moderate
aortic insufficiency and anMRI study showed the satisfactory
outcome of the surgical intervention on the aorta, excluding
the recurrence of any further dilatation in other aortic
regions.Moreover, both echocardiographic andMRI findings
were stable at last evaluation in February 2016, confirming the
persistence of the results of surgery.
After surgery, the follow-up strategy of a patient affected
by an aortic aneurysm resembles that used before aortic
repair, with differences in terms of frequency according to the
pathology and type of surgery (i.e., more frequent controls
for patients undergoing urgent surgery for dissection) [15].
Targets of clinical and therapeutic approaches are the same
as those utilized before surgical intervention. In MFS, in
particular, prosecution of 𝛽-blockers therapy and, possibly,
of TGF-𝛽-antagonism by ARB is recommended (unless
contraindicated). Transthoracic echocardiography is effective
in these patients for assessing the anatomy of the root aortic
prosthesis and the function of both the aortic and mitral
valve. Nonetheless, due to chest deformity, or other causes
of poor acoustic windows, echocardiography may not be
adequate in all the patients. Moreover, progressive aortic
dilatation can occur in other regions of the thoracic and
abdominal aorta, which are not amenable to ultrasound
scanning. Thus, periodic assessment with MR or CT scan of
the entire thoracoabdominal aorta is needed, with interval
between controls adjusted based absolute aortic size and
progression of the disease.
In conclusion, this case report demonstrates how family
history together with a comprehensive clinical and genetic
evaluation of patients with TAAD is necessary for clinical
diagnosis in order to achieve a documented differential diag-
nosis aimed at tailoring follow-up and therapeutic medical
and surgical strategies which may be noticeably different
based on different etiologies.
Such an approach requires a tertiary referral center in
order to offer a multidisciplinary assessment (to study the
systemic components defining either syndromic or non-
syndromic conditions), a coordinated multimodal imaging
approach, biomolecular and genetic skills, and, in selected
cases, surgical (pre- or postintervention) evaluation.
The need of genetic counseling should be strongly
reminded both before and after mutation screening analysis
in the center in which the analysis has been performed. The
genetic counseling is required independently of the purpose
of counseling itself (i.e., definition of diagnosis in potential
MFS, future prenatal diagnosis, and early diagnosis).
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